Dr. Laszlo Karai graduated summa cum laude with a medical degree and a Ph.D. from the Albert Szent-Gyorgyi Medical University, Szeged, Hungary. He started his residency in pathology in the Department of Pathology of the same university. He was awarded the Scholarship of the European Union (TEMPUS) in 1996 and continued his studies in surgical pathology at the University College London and at the Hammersmith Hospital in London, UK. Dr. Karai received his DipRCPath degree in surgical pathology after successful exams in London, and Cambridge, UK in 1998. His interest in research led him to the National Institutes of Health (NIH), Bethesda, MD, where he started Ph.D. work in molecular-neuroscience.
Dr. Karai’s findings on the pathomechanisms of pain led to a number of high impact scientific publications, and resulted in a Phase I Clinical Trial on the treatment of intractable pain at the National Cancer Institute (NCI). Dr. Karai re-trained in pathology with Dr. Elaine S. Jaffe at the Laboratory of Pathology of the NCI and gained experience in the diagnosis of cutaneous lymphoproliferative diseases, soft tissue pathology and in various dermatopathological conditions. He continued his training in dermatopathology focusing on hair pathology with a Fellowship Program at the Cleveland Clinic Foundation with Dr. Wilma F. Bergfeld in 2007.
Prior to his current position at DermDX, he was a Clinical Associate at Cockerell and Associates, Dallas, TX. Dr. Karai is the Acting Chair of the International Partnering Committee (IPC) of the American Society of Dermatopathologists, working with his colleagues on establishing connections with foreign countries. Dr. Karai has extensive teaching experiences in dermatopathology. He is board certified in Anatomic Pathology and Dermatopathology with special interest in cutaneous lymphomas, soft tissue tumors, pigmented lesions, inflammatory dermatoses, and teledermatopathology.
Melanoma Update with Regards to Immunotherapies
- Provide a historical overview on melanoma related immunotherapies
- Discuss various approaches and explain the science behind the therapy
- Discuss and review research protocols that could be part of future treatment modalities
- New advances in dermatologic treatment
- Development of new technology
- Advances in medical knowledge
Hinrichs CS, Rosenberg SA. “Exploiting the Curative Potential of Adoptive T-cell Therapy for Cancer”. Immunol Rev. 2014 Jan;257(1):56-71.
Rosenberg SA. “Decade in Review-Cancer Immunotherapy: Entering the Mainstream of Cancer Treatment”. Nat Rev Clin Oncol. 2014 Nov;11(11):630-2.
Wu R1, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG. “Adoptive T-cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma: Current Status and Future Outlook”. Cancer J. 2012 Mar-Apr;18(2):160-75.
Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale , Lash AE, Pirun M, Socci ND, Rutten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR. “Germline Mutations in BAP1 Predispose to Melanocytic Tumors”. Nat. Genet. 2011 Aug 28;43(10):1018-21.
Core Competencies: 2, 3, 6
- Provide a practical overview of new IHC stains used in dermatopathology
- Provide help with the interpretation of the stains
- New methods in dermatologic treatment
- Development of new technology
Ferringer T. “Immunohistochemistry in Dermatopathology”. Arch Pathol Lab Med. 2015 Jan;139(1):83-105. Doi: 10.5858/arpa.2014-0075-RA.
Wiesner T, He, J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, Lipson D, Otto G, Brennan K, Murali R, Garrido M, Miller VA, Ross JS, Berger MF, Sparatta A, Palmedo G, Cerroni L, Busam KJ, Kutzner H, Cronin MT, Stephens PJ, Bastian BC. “Kinase Fusions Are Frequent in Spitz Tumors and Spitzoid Melanomas”. Nat Commun. 2014;5:3116.
Folpe AL, Cooper K. “Best Practices in Diagnostic Immunohistochemistry: Pleomorphic Cutaneous Spindle Cell Tumors”. Arch Pathol Lab Med. 2007 Oct;131(10):1517-24.
Robson A. “Immunocytochemistry and the Diagnosis of Cutaneous Lymphoma”. Histopathology. 2010 Jan;56(1):71-90.
Core Competencies: 2, 6, 7